Pharmacokinetics, safety and efficacy study in pregnancy and existing cumulative data/evidence to support clinical use and labelling of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in pregnant women with HIV

Documenti analoghi

• Pharmacokinetic parameters of bictegravir in breastmilk of healthy, lactating volunteers without HIV after a single dose of 50 mg (co‐formulated with emtricitabine 200 mg and tenofovir alafenamide 25 mg)
  di: L. Van Der Wekken‐Pas, et al.
  Pubblicazione: (2025)
• Preclinical pharmacokinetics of novel long‐acting tenofovir alafenamide/bictegravir solid injectable in rats
  Pubblicazione: (2024)
• No observed bidirectional effect between tenofovir diphosphate concentrations and gender‐affirming hormone concentrations among transgender persons switching from tenofovir disoproxil fumarate/emtricitabine to tenofovir alafenamide/emtricitabine for HIV pre‐exposure prophylaxis
  di: Nimish Patel, et al.
  Pubblicazione: (2024)
• A preliminary analysis of the impact of pharmacogenetic variation on bictegravir and dolutegravir concentrations in individuals with HIV and tuberculosis
  di: A. Naidoo, et al.
  Pubblicazione: (2025)
• Dose proportionality and half‐life of tenofovir in hair samples from those with differing adherence to TDF or TAF‐based regimens monitored by directly observed therapy
  Pubblicazione: (2024)